29Aug 2023
Impact of Background Medical Therapy on Dapagliflozin Efficacy and Safety in Improved Ejection Fraction Patients

Impact of Background Medical Therapy on Dapagliflozin Efficacy and Safety in Improved Ejection Fraction Patients

A study assessed Dapagliflozin in Heart Failure patients with improved ejection fraction (HFimpEF) showed consistent efficacy and safety across different background medical therapies. The trial's 2.3-year follow-up demonstrated reduced heart failure events, particularly in patients on fewer therapies at baseline. Dapagliflozin didn't impact existing therapy use and was added safely to triple-medication cases. A promising stride toward managing HFimpEF and enhancing patient lives.

  • #cardiology

Like

Save

Share